[{"address1": "117, Avenue de Luminy", "address2": "BP 30191", "city": "Marseille", "zip": "13009", "country": "France", "phone": "33 4 30 30 30 30", "fax": "33 4 30 30 30 00", "website": "https://www.innate-pharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory s\u00e9zary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.", "fullTimeEmployees": 168, "companyOfficers": [{"maxAge": 1, "name": "Mr. Yannis  Morel Ph.D.", "age": 50, "title": "Executive VP, COO & Member of Executive Board", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 402284, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jonathan E. Dickinson", "age": 55, "title": "Chairman of the Executive Board & CEO", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Fran\u00e7ois  Romagn\u00e9 Ph.D.", "age": 59, "title": "Founder", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Eric  Vivier D.V.M., M.B.A., Ph.D.", "age": 59, "title": "Founder, Senior VP & Chief Scientific Officer", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marc  Bonneville Ph.D.", "age": 63, "title": "Founder", "yearBorn": 1960, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jean Jacques Fourni\u00e9 Ph.D.", "title": "Founder", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alessandro  Moretta M.D., Ph.D.", "title": "Founder", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Frederic  Lombard M.B.A.", "age": 48, "title": "Senior VP & CFO", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sonia  Quaratino M.D., Ph.D.", "age": 56, "title": "Executive VP, Chief Medical Officer & Member of Executive Board", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Arvind  Sood", "title": "Executive VP, President of US Operations & Member of Executive Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.11, "open": 2.11, "dayLow": 2.045, "dayHigh": 2.13, "regularMarketPreviousClose": 2.11, "regularMarketOpen": 2.11, "regularMarketDayLow": 2.045, "regularMarketDayHigh": 2.13, "beta": 0.868, "forwardPE": 4.6906667, "volume": 33305, "regularMarketVolume": 33305, "averageVolume": 483622, "averageVolume10days": 1522780, "averageDailyVolume10Day": 1522780, "bid": 2.09, "ask": 2.15, "bidSize": 400, "askSize": 400, "marketCap": 174739824, "fiftyTwoWeekLow": 1.29, "fiftyTwoWeekHigh": 3.511, "priceToSalesTrailing12Months": 5.1716533, "fiftyDayAverage": 1.82168, "twoHundredDayAverage": 2.217645, "currency": "USD", "enterpriseValue": 109653104, "profitMargins": -1.00781, "floatShares": 31561091, "sharesOutstanding": 82783696, "sharesShort": 62946, "sharesShortPriorMonth": 65217, "sharesShortPreviousMonthDate": 1730332800, "dateShortInterest": 1732838400, "sharesPercentSharesOut": 0.0008, "heldPercentInstitutions": 0.00503, "shortRatio": 5.63, "shortPercentOfFloat": 0.0014, "impliedSharesOutstanding": 84417000, "bookValue": 0.356, "priceToBook": 5.9292135, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -34052000, "trailingEps": -0.44, "forwardEps": 0.45, "enterpriseToRevenue": 3.245, "enterpriseToEbitda": -3.049, "52WeekChange": -0.22426468, "SandP52WeekChange": 0.2729931, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "IPHA", "underlyingSymbol": "IPHA", "shortName": "Innate Pharma S.A.", "longName": "Innate Pharma S.A.", "firstTradeDateEpochUtc": 1571319000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "95b2a86c-03b1-3402-a4e5-5bdc8b44e164", "messageBoardId": "finmb_426137", "gmtOffSetMilliseconds": -18000000, "currentPrice": 2.1108, "targetHighPrice": 11.5, "targetLowPrice": 2.56, "targetMeanPrice": 7.412, "targetMedianPrice": 8.0, "recommendationKey": "none", "numberOfAnalystOpinions": 5, "totalCash": 91799000, "totalCashPerShare": 1.134, "ebitda": -35959000, "totalDebt": 35503000, "quickRatio": 2.763, "currentRatio": 2.919, "totalRevenue": 33788000, "debtToEquity": 123.291, "revenuePerShare": 0.419, "returnOnAssets": -0.13758, "returnOnEquity": -0.78587997, "freeCashflow": 13058625, "operatingCashflow": -18057000, "revenueGrowth": -0.693, "grossMargins": -0.58769, "ebitdaMargins": -1.06425, "operatingMargins": -2.13147, "financialCurrency": "EUR", "trailingPegRatio": null, "__fetch_time": "2024-12-28"}]